9 October 2024 · 1 min read
A truly interesting talk from Gilead's Patrick Loerch on creating real AI value in Biopharma at ...
At BiotechX in Basel, Gilead's Patrick Loerch outlined what it really takes for AI to create value in biopharma — from systemic business impact to decision-making influence. I found his take on centralized vs. distributed AI models, regulatory coordination, and clinical value chain opportunities particularly compelling.
Author
Last updated
6 May 2026
A truly interesting talk from Gilead's Patrick Loerch on creating real AI value in Biopharma at BiotechX in Basel
Three things you need for AI to succeed:
- systemic business impact
- measurable value
- decision-making influence
It is still unclear whether a centralized CoE type model or a more distributed model for AI expertise works better, with Patrick advocating for a mixed model. Same applies for decision making.
Increasing regulation requires a coordinated response within big pharma companies.
Significant opportunities exist within a lot of use cases in the clinical value chain, including faster decision making, faster execution, and better data generation.